Bracco gets rights to phage display technology:
This article was originally published in Clinica
Executive Summary
Milan, Italy-based Bracco will pay $3 million for a worldwide exclusive licence to Dyax's proprietary phage display technology to develop imaging products. Bracco will pay Cambridge, Massachusetts-based Dyax a further $3 million per year in funding over the next three to six years, as well as development milestones and royalties. Phase display is a discovery method to identify proteins, peptides and human monoclonal antibodies that bind to diagnostic and therapeutic targets. The agreement covers the right to develop and commercialise existing Dyax product leads in inflammation, cardiovascular and oncology imaging.